Sirnaomics

Company Overview

Sirnaomics is a groundbreaking biopharmaceutical company specializing in oncology clinical-stage RNA therapeutics. As the first to achieve positive Phase IIb clinical outcomes, the company has established a strong presence in both Asia and the U.S. Their focus is on discovering and developing innovative drugs for indications with significant unmet medical needs and substantial market opportunities.

Leveraging on their two exclusive delivery platforms; PNP and GalAhead, Sirnaomics has developed an extensive clinical pipeline. Initially concentrated on oncology and fibrosis therapeutics, it’s now expanding into anticoagulant treatments, cardiometabolic disorders, complement-mediated ailments, medical aesthetics, and viral infections. Their primary drug candidates, STP705 for local administration in Non-Melanoma Skin Cancer (NMSC) treatment, and STP707 for intravenous use in solid tumor treatment, have both shown promising clinical outcomes in their respective trials.

The company’s subsidiary, RNAimmune, Inc., is a pioneering biotech company dedicated to the development of mRNA-based therapeutics and vaccines. With headquarters in Germantown, Maryland, USA, and a China headquarters in International BioIsland, Guangzhou, RNAimmune is committed to addressing unmet medical needs by harnessing messenger RNA technology to create innovative solutions for infectious diseases, cancer, and other health challenges.

The company’s diverse pipeline includes vaccines for infectious diseases (RSV, COVID-19, influenza, HSV, etc.) and cancer vaccines (RAS, NY-ESO-1), along with mRNA-encoded antibodies. RNAimmune has achieved significant potential and emerged as a leader in the field of mRNA vaccines and therapeutics.